Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/38529
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Buendía Rodríguez, Jefferson Antonio | - |
dc.contributor.author | Justinico Castro, José Armando | - |
dc.contributor.author | Tapia Vela, Laura Joanna | - |
dc.contributor.author | Sinisterra Espejo, Denis María | - |
dc.contributor.author | Sánchez Villamil, Juana Patricia | - |
dc.contributor.author | Zuluaga Salazar, Andrés Felipe | - |
dc.date.accessioned | 2024-03-10T01:00:51Z | - |
dc.date.available | 2024-03-10T01:00:51Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Buendía JA, Justinico Castro JA, Vela LJT, Sinisterra D, Sánchez Villamil JP, Zuluaga Salazar AF. Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage. BMC Res Notes. 2019 Sep 18;12(1):584. doi: 10.1186/s13104-019-4598-0. | spa |
dc.identifier.uri | https://hdl.handle.net/10495/38529 | - |
dc.description.abstract | ABSTRACT: Objective: The aim of this study was to compare in vivo efect of fve pharmacological options on infammation and pulmonary fbrosis induced by paraquat. Methods: 54 Wistar SPF rats were used. After 2 h post-intoxication with paraquat ion, groups of 9 animals were ran domly assigned to (1) cyclophosphamide plus dexamethasone (2) low molecular weight heparin (3) unfractionated heparin (4) vitamin C every 24 h, (5) atorvastatin or (6) placebo with intraperitoneal saline. Lung infammation, alveolar injury, hepatocyte damage, hepatic regeneration, acute tubular necrosis and kidney congestion were evaluated. Results: In the control group 100% of animals presented moderate and severe lung infammation, while in the groups with atorvastatin and intratracheal heparin this proportion was lower (55.5%; CI 26.6–81.3%) (p=0.025). A lower degree of moderate or severe hepatic regeneration was evident in the treatment groups with atorvastatin (p=0.009). In this study was demonstrated that statins and heparin might have a protective efect in the paraquat induced destructive phase. More evidence is needed to evaluated of dose–response efects of these drugs before to study in clinical trials | spa |
dc.format.extent | 5 páginas | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | BMC (BioMed Central) | spa |
dc.type.hasversion | info:eu-repo/semantics/publishedVersion | spa |
dc.rights | info:eu-repo/semantics/openAccess | spa |
dc.rights.uri | http://creativecommons.org/licenses/by/2.5/co/ | * |
dc.title | Comparison of four pharmacological strategies aimed to prevent the lung infammation and paraquat-induced alveolar damage | spa |
dc.type | info:eu-repo/semantics/article | spa |
dc.publisher.group | Grupo de Investigación en Farmacología y Toxicología | spa |
dc.identifier.doi | 10.1186/s13104-019-4598-0 | - |
oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.rights.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
dc.identifier.eissn | 1756-0500 | - |
oaire.citationtitle | BMC Research Notes | spa |
oaire.citationstartpage | 1 | spa |
oaire.citationendpage | 5 | spa |
oaire.citationvolume | 12 | spa |
oaire.citationissue | 1 | spa |
dc.rights.creativecommons | https://creativecommons.org/licenses/by/4.0/ | spa |
oaire.fundername | Colombia. Ministerio de Ciencia, Tecnología e Innovación | spa |
dc.publisher.place | Londres, Inglaterra | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
dc.type.redcol | https://purl.org/redcol/resource_type/ART | spa |
dc.type.local | Artículo de investigación | spa |
dc.subject.decs | Antioxidantes - Farmacología | - |
dc.subject.decs | Antioxidants - pharmacology | - |
dc.subject.decs | Ácido Ascórbico - Farmacología | - |
dc.subject.decs | Ascorbic Acid - pharmacology | - |
dc.subject.decs | Atorvastatina | - |
dc.subject.decs | Atorvastatin | - |
dc.subject.decs | Pulmón | - |
dc.subject.decs | Lung | - |
dc.subject.decs | Paraquat | - |
dc.subject.decs | Ciclofosfamida | - |
dc.subject.decs | Cyclophosphamide | - |
dc.subject.decs | Dexametasona | - |
dc.subject.decs | Dexamethasone | - |
dc.subject.decs | Quimioterapia Combinada | - |
dc.subject.decs | Drug Therapy, Combination | - |
dc.subject.decs | Heparina de Bajo-Peso-Molecular | - |
dc.subject.decs | Heparin, Low-Molecular-Weight | - |
dc.subject.decs | Neumonía | - |
dc.subject.decs | Pneumonia | - |
dc.subject.decs | Alveolos Pulmonares | - |
dc.subject.decs | Pulmonary Alveoli | - |
dc.subject.decs | Fibrosis Pulmonar | - |
dc.subject.decs | Pulmonary Fibrosis | - |
dc.subject.decs | Ratas Wistar | - |
dc.subject.decs | Rats, Wistar | - |
dc.subject.decs | Resultado del Tratamiento | - |
dc.subject.decs | Treatment Outcome | - |
dc.description.researchgroupid | COL0039902 | spa |
oaire.awardnumber | 833-2015 | spa |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D000975 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D001205 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D000069059 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D008168 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D010269 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D003520 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D003907 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D004359 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D006495 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D011014 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D011650 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D011658 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D017208 | - |
dc.subject.meshuri | https://id.nlm.nih.gov/mesh/D016896 | - |
dc.relation.ispartofjournalabbrev | BMC Res. Notes. | spa |
oaire.funderidentifier.ror | RoR:03fd5ne08 | - |
Aparece en las colecciones: | Artículos de Revista en Ciencias Médicas |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
BuendiaJefferson_2019_Comparison_Four_Pharmacological_Strategies.pdf | Artículo de investigación | 810.18 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons